LONDON BROKER RATINGS: UBS raises 3i Group; Exane BNP cuts BT
2nd Oct 2025 09:49
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - The FTSE 100 hit another record high on Wednesday, despite concerns over the US shutdown, as pharmaceutical stocks powered higher, with AstraZeneca up 11% alone. Read More
(Alliance News) - Daiichi Sankyo Co Ltd on Wednesday said its breast cancer therapy, developed alongside Cambridge, England-based pharmaceuticals firm AstraZeneca PLC, has been accepted for review in the US. Read More
(Alliance News) - Stock prices in London were higher at midday on Wednesday as markets got over a wobble on the shutdown of the US government, while the blue-chip index was pushed higher due to a surge in pharmaceutical firms. Read More
(Alliance News) - Stock prices in London opened higher on Wednesday, and the FTSE 100 reached a new intra-day record, shaking off any jitters as the US government shut down overnight. Read More
(Alliance News) - ConvaTec Group PLC on Wednesday unveiled plans for a new research & development site in Manchester as part of more than USD1 billion of investment in the UK and US over the next decade. Read More
(Alliance News) - The FTSE 100 made a solid start to the trading week on Monday as the UK chancellor pledged continued fiscal restraint and gains in mining stocks offset falls in oil majors. Read More
(Alliance News) - Stock prices in London were higher at midday on Monday, shaking off the shadow of a possible US government shutdown, as the appointment of a new boss at GSK was well received by investors. Read More
(Alliance News) - AstraZeneca PLC on Monday announced plans to upgrade its US listing but said it will keep its London trading and UK headquarters. Read More
(Alliance News) - GSK PLC Chief Executive Emma Walmsley will step down from the start of next year, the pharmaceutical firm announced Monday, with chief commercial officer Luke Miels named as its next boss. Read More
(Alliance News) - Stock prices in London opened higher on Monday amid gains for GSK and AstraZeneca, while the gold price continued to climb. Read More
(Alliance News) - AstraZeneca plans changes to its US listing and to retain its position in London, GSK promotes its chief commercial officer to lead the company while Merchants Trust raises its dividend. Read More
(Alliance News) - The FTSE 100 recorded strong gains on Friday as US data pointed to resilient consumer spending and relatively subdued inflation, keeping hoped for rate cuts across the pond on track. Read More
(Alliance News) - Stocks in London fell on Thursday and the pound dipped - while strong US data boosted the dollar - as talk of a political challenge to Keir Starmer saw UK bond yields climb. Read More
(Alliance News) - London stocks were mixed at midday on Wednesday, following a Wall Street slump on Tuesday as investors digested US President Donald Trump's turnaround on the conflict in Ukraine. Read More
(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Wednesday said the US Food & Drug Administration has granted priority review for Enhertu in combination with pertuzumab as a first-line treatment for adults with HER2-positive metastatic breast cancer. Read More
(Alliance News) - Blue chips in London faded into the close on Tuesday, ending little changed, as worries over economic growth and inflation overshadowed strong results from Kingfisher. Read More
(Alliance News) - AstraZeneca PLC on Monday said two drugs have been recommended for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More
(Alliance News) - London's FTSE is set to open lower on Monday, following a rate hold by China's central bank and the risk of heightened geopolitical tensions following the recognition of a Palestinian state by the UK, Australia, Canada and Portugal over the weekend. Read More
(Alliance News) - AstraZeneca PLC on Friday said new long-term clinical trial data reinforce Ultomiris as a transformative treatment for neuromyelitis optica spectrum disorder, or NMOSD, a rare autoimmune disease that can cause blindness and paralysis. Read More